News

The European Commission is asking scientists, industrialists and members of the public to help it draft a code of conduct for nanotechnology.

Hillary Clinton, the Democrat Senator from New York, has received an honorary doctorate of medicine from Göteborgs Universitet for her efforts to improve healthcare in the US. A ceremony is expected to take place in the United States in the autumn of 2007.

Pharming Group NV said that it has made “important progress” in the process of developing and obtaining registration for its recombinant human C1 inhibitor, Rhucin.

The European Medicines Agency has called for the withdrawal from the European market of the neuroleptic, veralipride, following reports of severe side effects.

Five medicinal products, including a generic version of olanzapine, have been recommended for licensing in Europe by the main scientific committee of the European Medicines Agency (EMEA). At the same time, a proposed treatment for Crohn’s disease from Elan Pharma, was turned back.

Researchers at the Karolinska Institutet in Sweden have described the structure of a human membrane protein that is understood to have a major influence on the development of asthma.

UK universities created 187 spin-off companies in the 2005-06 academic year, according to a government survey.

Cambridge Research Biochemicals (CRB) is preparing to investigate a new method for validating antibodies using technology based at Newcastle University and funded by one of the UK’s regional development authorities.

From 7 July 2007, pharmaceutical companies holding European Community marketing authorisations could be fined at up to 5% of their Community turnover if they infringe their licensing obligations or give false information to the European Medicines Agency (EMEA).

Vivalis, a French company that has developed a stem cell technology for the manufacture of vaccines, has made an initial public offering of shares on the mid-cap section of the Euronext Paris stock exchange, worth about €46.4 million.